A single dose therapy to treat drug resistant gonorrhea
Ended Project Grant Awarded Last action
- Award ID
- R44AI184024
- Recipient
-
Aimmax Therapeutics Inc. UEI VCBNGNMH78J9
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $919,491
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date
- Originally
- Place of performance
- North Carolina, USA
Award details come from USAspending.gov.
Description
- Abstract
- Gonorrhea is a sexually transmitted infection caused by n. Gonorrhoeae. In recent years, the number of people with gonorrhea infections in the US has steadily increased, with more than 700,000 infections reported in 2021. N. Gonorrhoeae has proven adept at acquiring resistance to every single antimicrobial therapy used for its treatment in history, starting with the sulfonamides in the 1930S and then penicillin, tetracyclines, fluoroquinolones, oral cephalosporins, and macrolides. In the past decade, there have been reports of strains resistant to the last remaining recommended treatment, ceftriaxone. Thus, we are on the precipice of returning to a pre-antibiotic ERA of untreatable gonorrhea. Left untreated, gonorrhea infections can cause serious or life- threatening sequelae including infertility and ectopic pregnancy in women, and, if disseminated to the blood, may lead to complicated infections resulting in cardiovascular and neurological problems. Further, vertical transmission to neonates can lead to blindness or life-threatening bloodstream infections if not promptly treated. In this fast track sbir grant, we propose to develop an intramuscular (IM) injection formulation of an innovative antibiotic, AMX-2005, as a first-in-class, single dose therapy for the treatment of drug-resistant gonorrhea. A single dose regimen is currently the preferred therapeutic paradigm to treat gonorrhea by the treating physicians and public health organizations such as the world health organization due to concerns surrounding dosing compliance in some patients and the threat this poses to on-therapy resistance emergence and continued spread of infection in the community. We believe that a single dose therapy is most likely achieved with a non-oral antibiotic based on PK-PD considerations. AMX-2005 possesses numerous microbiological attributes that are desirable as an antibiotic for the treatment of drug-resistant gonorrhea such as lack of cross-resistance to other antibiotics (including high-level ceftriaxone- and azithromycin-resistant strains), low potential for resistance development (spontaneous mutation frequencies
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $306,497 | |
| Amendment | $306,497 | |
| Original award | $306,497 |
Quick answers
Who received award R44AI184024?
R44AI184024 was awarded to Aimmax Therapeutics Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on April 1, 2024.
How much is award R44AI184024 worth?
$919,491 has been obligated on R44AI184024.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award